Skip to content

CytoSorbents to commercialize CytoSorb in Northeast, Mid-Atlantic, Fla.

August 17, 2020

CytoSorbents (NASDAQ:CTSO) has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb under its FDA Emergency Use Authorization (EUA) in adult, critically-ill, COVID-19 patients with imminent or confirmed respiratory failure.

Covering 15 states, Surgical Partners and InvoSurg will work with CytoSorbents to sell and distribute CytoSorb in Florida, and the Northeast and Mid-Atlantic U.S., from Maine to Virginia, respectively.

“CytoSorb is the only FDA EUA blood purification technology to target cytokine storm reduction using CytoSorbents’ proprietary, highly biocompatible polymer beads,” stated Mr. Chris Cramer, Vice President of Business Development of CytoSorbents.

Financial terms are not disclosed.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: